• ArsenalBio Launches With $85M for “Programmable” T Cell Therapies

    1 month ago - By Xconomy

    Cell therapies are made by tinkering with a patient's immune cells so that they can better recognize and destroy cancer cells. These drugs give patients another treatment option for certain cancers that haven't responded to anything else. ArsenalBio CEO Ken Drazan aims to take cell therapy even further. Arsenal is developing technology that adds capabilities to a cell therapy similar to the way a software programmer stacks new functions on a computer program. Improving the way a therapy finds its cancer target is one way Arsenal could “program” a cell, Drazan says. On top of that, a...
    Read more ...

     

  • ArsenalBio joins next-gen cell therapy field with $85M A round

    ArsenalBio joins next-gen cell therapy field with $85M A round

    1 month ago - By Fierce Biotech

    ArsenalBio has exited stealth with $85 million to discover and develop cell therapies. The biotech aims to differentiate itself from the ever-growing pack of cell therapy startups with technology that enables the insertion of large DNA sequences without the use of viral vectors.
    Read more ...